A study in JAMA Network Open found that a telemedicine-supported home injection model can reduce the practical burden for breast cancer patients receiving injectable gonadotropin-releasing hormone agonist therapy. The investigation evaluated a shift of care from clinic administration to at-home dosing with remote support. The approach aims to lower the logistical demands of repeated in-person visits while maintaining care oversight through telemedicine. For oncology programs, the data add to a growing body of evidence that structured virtual care models can be integrated into long-duration endocrine treatment workflows. If adopted more broadly, these models could influence how health systems staff infusion and injection services while affecting patient adherence and time-to-treatment continuity.